News
Thursday 1 January 2015
Professor Nigel Sparrow, chair of Target Ovarian Cancer's GP Advisory Board, was awarded an OBE for services to primary care in the New Year’s Honours List for 2015.  Joanna Barker, Target Ovarian Cancer’s chairman, said: “The Board of Trustees and everyone at Target Ovarian Cancer extends our...
News
Monday 22 December 2014
The National Institute for Health and Care Excellence (NICE) have today published the draft guidance on their recent Multiple Technology Appraisal of certain ovarian cancer drugs. The NICE committee has been consulting on a review of the use of topotecan (Hycamtin), pegylated liposomal doxorubicin...
News
Friday 19 December 2014
You may have read or heard the news that the drug olaparib (to be marketed as Lynparza) has been approved by the European Commission, to be used by women with platinum-sensitive relapsed BRCA1 or BRCA2 mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who...
Blog
Wednesday 17 December 2014
Last month I was lucky enough to join our Research Advocates on a fascinating visit to the University of Nottingham. There we met the enthusiastic Dr Srinivasan Madhusudan and his colleague Dr Rachel Doherty who are conducting research into potential ways to increase the effectiveness of...

Pages